Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it
Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it has entered into negotiation for the purpose of filing an application in Jamaica for the purpose of growing and exporting medical concentrated Marijuana into various countries including Canada, Mexico, and Brazil.
Easton Pharmaceuticals has previously demonstrated its strong desire and commitment to enter the lucrative market of medical marijuana. To further demonstrate its commitment, Easton can now confirm and disclose it has been in negotiations with several advanced staged license applicants in both Canada and now Jamaica. The countries of Mexico and Brazil currently allow the importation of Marijuana, while Canada is expected to federally approve Marijuana for recreational use in the spring of 2017. Many other states in the United States have also recently passed legislation approving it.
Marijuana can easily be grown outdoors in Jamaica’s moderate climate, which substantially reduces the various costs, providing increased margins and profitability as opposed to Canada where it is grown indoors with many stringent regulations and up front infrastructure costs necessary for production. Easton believes it can export concentrated medicinal marijuana through its distribution network in Mexico and other parts of Latin America where the importation of medical marijuana is legal. The company further believes it can be one of the first to supply medicinal concentrated marijuana to licensed producers in Canada.
The fast growing and increasingly accepted Medical Marijuana industry is believed to be a good compliment to Easton’s other existing business sectors which includes its licensed patented woman’s diagnostic products (VagiSan (VS-Sense), AmnioSense (AL-Sense), Gynofit) and its two generic cancer drugs (Pacletaxel & Docetaxel) licensed through BioLyse Pharma.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical device and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica and together, own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic and preventative care products, along with two generic cancer drugs Paclitaxel and Docetaxel.
Easton Pharmaceuticals Inc (EAPH) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...
Continue Reading
A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...
Continue Reading
Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...
Continue Reading
Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...
Continue Reading
The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...
Continue Reading
The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...
Continue Reading
Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...
Continue Reading
Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...
Continue Reading
A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...
Continue Reading
Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...
Continue Reading
Top 5 Most Recently Viewed Articles
David Deamer's Remarkable Recognition Renowned scientist David Deamer, Ph.D., has been honored for his extraordinary contributions to biomolecular technologies. This distinguished recognition comes from the Association of Biomolecular Resource Facilities (ABRF), which named Deamer the recipient of their prestigious ABRF Award, an accolade given to those who have made...
Continue Reading
Qualcomm's Stock Performance Qualcomm Inc. (NASDAQ: QCOM) is experiencing a decline in its stock price as recent analyst evaluations raise concerns regarding its future earnings potential. This downward trend follows, in part, an important downgrade by analysts highlighting challenges ahead for the company. Understanding the Downgrade KeyBanc analyst John Vinh made...
Continue Reading
Intensity Therapeutics Regains Nasdaq Compliance Intensity Therapeutics, Inc. (NASDAQ: INTS) is excited to share significant news regarding its compliance status with Nasdaq's minimum stockholders' equity requirement. The company, committed to developing innovative intratumoral cancer therapies, recently received a notification from the Listing Qualifications Staff of The...
Continue Reading
Strong Financial Performance from Resmed Inc. Resmed Inc. (NYSE: RMD, ASX: RMD) has announced impressive financial results for its latest quarter, indicating clear growth and sustained demand for its innovative health solutions in sleep and breathing fields. The company's revenue saw an encouraging year-over-year increase of 8%, rising to $1.3 billion. Notably, this...
Continue Reading
Fangzhou Brings Otsuka's Ponatinib to Patients Fangzhou Inc., a leader in innovative healthcare solutions, has announced the launch of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor. This groundbreaking treatment is known as Ponatinib, also branded as Iclusig® and is now accessible through Fangzhou's online platform. This offering significantly...
Continue Reading